Arbutus Biopharma Corporation (ABUS) Q1 2024 Earnings
ABUS·Reported May 2, 2024·Before market open
Arbutus Biopharma Corporation reported Q1 2024 revenue of $1.5M, missed analyst consensus of $2.2M by $618.0K. Diluted EPS came in at $-0.10.
Revenue
$1.5Mmissed by $618.0K
Consensus: $2.2MDiluted EPS
$-0.10met estimate
Consensus: $-0.10
Financial Snapshot
Trailing eight quarters through Q1 2024
Q1 2024 Earnings FAQ
Common questions about Arbutus Biopharma Corporation's Q1 2024 earnings report.
Arbutus Biopharma Corporation (ABUS) reported Q1 2024 earnings on May 2, 2024 before market open.
Arbutus Biopharma Corporation reported revenue of $1.5M and diluted EPS of $-0.10 for Q1 2024.
Revenue missed the consensus estimate of $2.2M by $618.0K. EPS beat the consensus estimate of $-0.10 by $0.00.
You can read the 10-Q periodic report (0001447028-24-000038) directly on SEC EDGAR. The filing index links above go to sec.gov.